FDA scientists said none of the popular drugs have been proven safe or effective. Source: Ars Technica · Summarized by HeadlinesBriefing Related articlesAlibaba Leaders’ Buying Does Little to Ease Share Sale FalloutAlphabet Loses $692 Billion in Market Value as AI Questions RiseAsian Stocks Set to Extend AI Chip-Fueled Selloff: Markets WrapAsia Tech Shares Swing Wildly as A.I. Jitters PersistAdvantest Shares Decline After Outlook Misses on Tight CapacityMore from Ars TechnicaMeta may use sweeping new commercial TOS to avoid millions in AI licensing feesPolymarket saw $600 million in election trades after the elections were overTesla turns to 50-year-old stunt technology as it tries to Roadster againSuper Scam Me documentary shows what it takes to catch a romance scammerThe Surface Laptop Ultra delivers on most of Microsoft's promisesLatest in Tech & GamesPulsar Feinmann F01 Noctua Edition Review · TechPowerUp ReviewsPowerColor Readies Low-Profile Radeon RX 9050 8 GB for Small Form Factor PCs · TechPowerUp NewsChinese Startup Unveils First Homegrown EUV Laser Source · TechPowerUp NewsArc Raiders Launches to 6-Month High After Free Weekend, PvE-Only Test, and Frozen Trail Update · TechPowerUp NewsThe Blood of Dawnwalker Update 1.1 Arrives Next Week With Skill Respec and New Difficulty · TechPowerUp NewsRelated briefingsTech & Mobile 24-Hour BriefingTech & Mobile 8-Hour BriefingHomeTech & GamesRFK Jr. proposes FDA look the other way on unproven peptides, report…SectionsHomePublic MarketsPrivate MarketsTech & GamesMobileDeveloperF1SportsOther languagesEnglish简体中文Españolहिन्दीالعربيةFrançaisবাংলাPortuguêsРусский日本語DeutschBahasa Indonesia